Predictive values of clinicopathological features and expression of thyroid transcription factor 1 for epidermal growth factor receptor mutations in non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2018.01.002
- VernacularTitle:临床病理特征及甲状腺转录因子1表达对非小细胞肺癌表皮生长因子受体突变的预测价值
- Author:
Shuxiong TIAN
1
;
Yongan ZHOU
;
Jinfen WANG
;
Yanfeng XI
;
Peixian LIU
;
Chao LI
;
Xia HOU
;
Min LI
Author Information
1. 山西医科大学研究生学院
- Keywords:
Carcinoma;
non-small-cell lung;
DNA mutational analysis;
Receptor;
epidermal growth factor;
Thyroid nuclear factor 1
- From:
Cancer Research and Clinic
2018;30(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the values of clinicopathological features and expression of thyroid transcription factor 1 (TTF-1) in predicting the mutation status of epidermal growth factor receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC). Methods Mutation status of exons 18, 19, 20 and 21 in EGFR, and expression of TTF-1 protein in 283 cases of NSCLC diagnosed in Shanxi Provincial Cancer Hospital from January 2013 to December 2014 were analyzed by using amplification refractory mutation system (ARMS) and immunohistochemical method. The correlation of EGFR mutations with the clinicopathological features and TTF-1 expression were studied to explore the values of them in the prediction of EGFR mutations. Results Among 283 cases of NSCLC, the rate of EGFR gene mutation was 30.0 ％(85/283), including 3 cases with double mutations(exon 18 and exon 20 double mutations in one case, exon 19 and exon 21 double mutations in one case, exon 20 and exon 21 double mutations in one case). The EGFR gene mutations were associated with gender, histological type, history of smoking, and expression of TTF-1 (all P<0.001), but not related to age and tumor location (P= 0.785, P= 0.138). The combination of factors with high mutation rates (women, adenocarcinoma, no smoking, and TTF-1 positive) made the positive predictive value of EGFR mutations up to 57.6 ％. And the combination of factors with low mutation rates (male, nonadenocarcinoma, smoking history, TTF-1 negative) made the EGFR negative predictive value up to 90.3％. Conclusion The combination of clinicopathological features and TTF-1 expression status in patients with NSCLC has a great predictive value for EGFR mutations, which can provide a useful reference for clinical treatment decision-making.
